Kornimate/medical-research-clean huggingface dataset:
effect of mindful eating on weight management in breast cancer survivors

Conditions: Breast Neoplasm Female

Summary: this pilot study examined changes in anthropometric measures as a result of and feasibility/ acceptability of a mindful eating intervention for overweight and obese postmenopausal breast cancer survivors.

being overweight is associated with increased risk for chronic disease and premature death in breast cancer survivors. this pilot study examined changes in anthropometric measures as a result of and feasibility/ acceptability of a mindful eating intervention for overweight and obese postmenopausal breast cancer survivors. the one-group pre-posttest study design included eight weekly group-based mindful eating sessions on strategies to intentionally and attentively consume food. anthropometrics, blood pressure, mindfulness, nutritional intake, and physical activity were collected at baseline and 12-weeks follow-up. data on feasibility and acceptability were collected at study completion.

Eligibility criteria:
inclusion criteria: * postmenopausal female * breast cancer survivor (in remission) * completed cancer treatment at the time of study enrollment * body mass index (bmi) equal or greater than 25 kg/m² exclusion criteria: * none.

Keywords: obesity mindful eating postmenopausal breast cancer survivors weight management cardiovascular health
reverse ramp pacing to terminate ventricular tachycardia ( rev-ramp)

Conditions: Arrythmia

Summary: cardiac pacing which involved stimulating the heart electrically with electrical wires that go into the heart is routine practice in the diagnosis and treatment of heart rhythm problems. clinically this involved the fields of cardiac pacing and electrophysiology. patients who are at risk of sudden death because of serious heart rhythms that are a result of malfunction of the electrical system of the pumping chambers of the heart (ventricles) are generally implanted with specialised pacemakers that can defibrillate (shock) the heart if a nasty life threatening rhythm should result. shocks are painful and in order to try and treat these rhythms without shocks, anti tachycardia pacing is performed (this is routine part of the device), which aims to interrupt the rhythm by stimulating the heart electrically. this does not always work and can destabilise the rhythm leading to a shock. revramp is a novel modification of anti tachycardia pacing which involved stimulating the heart through the defibrillator wires in a different way. it appears to work better and seems less likely to destabilise the heart rhythm, hence can reduce painful shocks.

cardiac pacing which involved stimulating the heart electrically with electrical wires that go into the heart is routine practice in the diagnosis and treatment of heart rhythm problems. clinically this involved the fields of cardiac pacing and electrophysiology. patients who are at risk of sudden death because of serious heart rhythms that are a result of malfunction of the electrical system of the pumping chambers of the heart (ventricles) are generally implanted with specialised pacemakers that can defibrillate (shock) the heart if a nasty life threatening rhythm should result. shocks are painful and in order to try and treat these rhythms without shocks, anti tachycardia pacing is performed (this is routine part of the device), which aims to interrupt the rhythm by stimulating the heart electrically. this does not always work and can destabilise the rhythm leading to a shock. revramp is a novel modification of anti tachycardia pacing which involved stimulating the heart through the defibrillator wires in a different way. it appears to work better and seems less likely to destabilise the heart rhythm, hence can reduce painful shocks.

Eligibility criteria:
inclusion criteria: * participants who are due to have a new defibrillator (including cardiac resynchronisation defibrillator) implant or box change exclusion criteria: * contraindications to defibrillator testing e.g. severe untreatable coronary disease intracardiac thrombus interruption of anticoagulation participants undergoing box change, device upgrade or revision inability or unwillingness to provide informed consent.
a smoking cessation trial in hiv-infected patients in south africa

Conditions: Smoking Cessation; HIV

Summary: the purpose of this study is to conduct a randomized controlled trial (rct) of intensive anti-smoking counseling plus nicotine replacement therapy versus intensive anti-smoking counseling alone among hiv-infected patients in south africa, and to concurrently measure the prevalence of smoking among hiv-infected patients in south africa.

tobacco use is estimated to be responsible for over 5 million deaths globally every year and hiv/aids kills 2 million worldwide, with persons living in the developing world especially at risk. however, the association between tobacco use and hiv is not clearly understood. the introduction of highly active antiretroviral therapy (haart) has led to longer duration of survival following hiv-infection in the developed world, and now that haart is being rolled out in the developing world, survival will increase in these highly endemic regions as well. given this increase in survival, more people will die of non-hiv related illnesses for which smoking plays an important causal role. smoking cessation for hiv-infected persons has been studied in the us though these studies have had small numbers and limited follow-up. us based studies suggest that approaches that combine nicotine replacement therapy (nrt) and counseling interventions are most successful. optimal approaches in resource-limited settings have not been determined. this study will compare intensive counseling plus nrt versus intensive counseling only, comparing smoking cessation at 2, 6 and 12 months. at 6 months, patients who are still current smokers will be given a second opportunity to receive their group assigned intervention, either intensive counseling plus nrt or intensive counseling alone. we will relate smoking exposure and cessation to hiv progression as measured by immunologic and viral markers, risk of respiratory infections, including tuberculosis, and aids-related malignancies. the rct will be performed at the tshepong hiv wellness clinic in klerksdorp, south africa, associated with the reproductive health \& hiv research unit of the university of the witwatersrand, south africa.

Eligibility criteria:
inclusion criteria: * current, daily smoker (biochemically verified via a positive result on the smokescreen® test from gfc diagnostics ltd., as described in the outcomes) * be willing to set a quit date within 2 weeks after baseline assessment * agree to participate in study and anticipated to be attending tshepong wellness clinic, jouberton community health center, or grace mokhomo community health center (due to hiv infection) for at least 6 months exclusion criteria: * pregnant or nursing * currently using smokeless tobacco (including electronic cigarettes, nrt or other cessation treatment) * tuberculosis confirmed case * weight \<45 kg or bmi \<20 * suffering from any unstable medical condition which could preclude use of the nicotine patch: * unstable angina * uncontrolled hypertension * active skin disease (e.g. psoriasis) * history of skin allergy

Keywords: smoking administration, cutaneous
clinical application of multi-modal sentinel lymph node staining method in breast cancer patients after neoadjuvant chemotherapy

Conditions: Sentinel Lymph Node Biopsy; Neoadjuvant Therapy; Breast Neoplasm

Summary: this clinical trial aimed to confirm the effectiveness of sentinel lymph node surgery by determining the lymph node identification rate using multimodal sentinel lymph node marker methods in patients with advanced breast cancer undergoing neoadjuvant chemotherapy (nac).

after nac, the sentinel lymph node (sln) identification rate is lower, and it has a higher false-negative rate than that in early-stage breast cancer. as appropriate sln surgery directly affects the treatment and prognosis of patients undergoing nac, evaluation to identify sln using various methods is necessary. this clinical trial aimed to confirm the effectiveness of sentinel lymph node surgery by determining the lymph node identification rate using multimodal sentinel lymph node marker methods in patients with advanced breast cancer undergoing neoadjuvant chemotherapy (nac).

Eligibility criteria:
inclusion criteria: * the patient with locally advanced breast cancer who achieved neoadjuvant chemotherapy * confirmed operability with imaging study after neoadjuvant chemotherapy * age over 20 years old * ecog performance status : 0-2 * the patient with written informed consent form exclusion criteria: * the patient with previous ipsilateral breast cancer history * the patinet with previous ipsilateral axillary surgical procedure (e.g. excisional or incisional biopsy, axillary dissection) * the patient without neoadjuvant chemotherapy * inoperable imaging study after neoadjuvant chemotherapy * inflammatory breast cancer * pregnant patient

Keywords: breast cancer sentinel node biopsy neoadjuvant chemotherapy
effect on blood flow using the flowox™ device in patients with reduced peripheral circulation in the lower leg

Conditions: Periferal Arterial Occlusive Disease, PAOD

Summary: a study to assess the effect of negative pulsating pressure therapy on patients with impaired blood flow to the leg caused by arterial disease, to see if the flowox device will increase the blood flow to the leg in these patients.


Eligibility criteria:
inclusion criteria: * written informed consent * age 30-90 years * affected foot/shoe sise less than 46 (approximate foot length less than 29.5 cm) * patients with peripheral arterial occlusive disease (paod) grade 2,3 or 4, i.e.: 1. clinically verified grade 2, i.e. intermittent claudication: * ancle-brachial index (abi)less than 0.9 or * toe brachial index (tbi) less than 0.7 or * ultrasound and/or ct/magnetic resonance (mr) angiography suggesting stenosis(es)and/or occlusion(s) 2. clinically verified grade 3, i.e. critical limb ischemia (cli): * abi less than 0.4 or * toe pressure less than 30 mmhg * rest pain since at least 2 weeks or * use of analgesics for rest pain for at least 2 weeks or * ultrasound and/or ct/magnetic resonance (mr) angiography suggesting stenosis(es)and/or occlusion(s) 3. clinically verified grade 4, i.e. cli: * ischemic ulcers or gangrene/tissue loss * abi less than 0.4 * toe pressure less than 30 mmhg * rest pain since at least 2 weeks or * use of analgesics for rest pain for at least 2 weeks or * ultrasound and/or ct/mr angiography suggesting stenosis(es)and/or occlusion(s) exclusion criteria: * grade 1 paod * incapable of consenting voluntarily * fewer higher than 39 degrees centigrade * severe chronic obstructive pulmonary disease (copd) * severe heart disease such as unstable angina, severe heart failure and severe valve failure * severe polyneurophathy * verified osteomyelitis other than in the phanlanx * currently treated for cancer and with a life expectancy of less than 2 years
efficacy of rilpivirine-based regimens as switch therapy from nevirapine-based regimens in hiv-infected patients

Conditions: Efficacy of Rilpivirine-based Regimens as Switch Therapy

Summary: background: nevirapine (nvp)-based antiretroviral therapy (art) remains to be used in hiv-infected patients in resource limited countries despite its compliance and adverse effect concerns. rilpivirine (rpv), a newer non-nucleoside reverse transcriptase inhibitor, could be used as an alternative to nvp in virologically suppressed patients. however, there has been limited experience with switching from nvp-based to rpv-based regimens. the investigators aimed to study efficacy and adverse events after art switching from nvp-based to rpv-based regimens. methods: a randomized controlled non-inferiority trial was conducted in hiv-infected patients who received nvp-based regimens and had undetectable plasma hiv rna for more than 6 months. patients were randomized 1:1 to continuation arm (nvp-based regimens were continued) or switch arm (nvp-based regimens were switched to rpv-based regimens). tenofovir disoproxil fumarate (tdf) plus lamivudine (3tc) or emtricitabine (ftc) remained as the backbone of the regimens. primary endpoint was hiv rna \<40 copies/ml at 48 weeks, with a non-inferiority margin of 12%. changes of cd4 cell counts and lipid profiles from baseline were analyzed.

a single-center randomized controlled, non-inferiority trial to study 48-week treatment outcomes of rpv as a switch therapy was conducted at ramathibodi hospital, a tertiary care health center in thailand from december 2016 to october 2017 eligible patients who currently received tdf/3tc/nvp (group a) or tdf/ftc/nvp (group b) were block 4 randomly assigned (1:1) by computer-generated random numbers, to continue their current regimen of nvp 200 mg twice daily plus tdf/3tc (group a1) and plus tdf/ftc (groupb1), or to switch from nvp to rpv 25 mg once-daily plus tdf/3tc (group a2) and plus tdf/ftc (groupb2). patients were advised to take rpv with a meal. patients were scheduled trial visits at baseline, week 12, 24, 36 and week 48. the laboratory assessment was performed at baseline week 24 and week 48.

Eligibility criteria:
inclusion criteria: * recent plasma hiv-1 rna viral load within 6 months of the screening that was less than 40 copies/ml, and a cd4 cell count that was more than 200 cells/mm3 * patient who treated with tdf/ftc/nvp or tdf/3tc/nvp for at least 6 month exclusion criteria: * patients with a history of hiv drug resistance, patients who used other drugs or drugs which interact with rpv (proton pump inhibitors, histamine h2-receptor antagonists, rifampin, antiepileptic drugs), female patients during pregnancy or breastfeeding, patients whose estimated glomerular filtration rate (egfr)was \<60 ml/min/1.73m2 \[by the chronic kidney disease epidemiology collaboration (ckd-epi) (12)\], and patients diagnosed with depressive or psychiatric disorders.

Keywords: rilpivirine switch therapy
cell population data in clpd and viral disease

Conditions: Chronic Lymphoproliferative Disease

Summary: hematological malignancies typically arise from two major blood cell lineages: lymphoid and myeloid cells . hematological malignancies are the fourth most frequently diagnosed cancer around the world . chronic lymphoproliferative disorders (clpd) comprise a heterogeneous group of diseases characterized by uncontrolled production of lymphocytes that cause monoclonal lymphocytosis, lymphadenopathy and bone marrow infiltration. these diseases often occur in immuno-compromised individuals. there are two subsets of lymphocytes: t and b cells that regenerate uncontrollably to produce immunoproliferative disorders, which are prone to immunodeficiency, a dysfunctional immune system, and lymphocyte dysregulation. several gene mutations have been described as causes of clpd that can be iatrogenic or acquired . viral infections induce lymphocyte activation, undifferentiated lymphocyte proliferation, and antibody or cytokine/lymphokine secretion. the immune defense against viral infection is more dependent on t cells and less dependent on antibodies. cytotoxic t cells are important in killing virally infected cells. a number of cytokines, including interferon gamma and tumor necrosis factor (tnf), are secreted by the cytotoxic t cells.1it is conceivable that the activated lymphocytes may undergo not only morphologic changes, such as an increase in size, but also alterations in cytoplasmic composition as compared to their normal 'resting' counterparts . beyond the differential leukocyte count, modern hematological analyzers provide additional quantitative data known as "cell population data (cpd) which is regarded as the fingerprint of a blood cell at a given moment. cpd parameters harbor information associated with cell morphology and offer detailed information about the size, complexity, and fluorescence characteristics of different cell populations, potentially aiding in the diagnosis and management of various haematological conditions . there has been no comprehensive study on the usefulness of cell population data (cpd) parameters as a screening tool in the discrimination of non-neoplastic(viral infection) and neoplastic haematological disorders such clpd. the aim of the study evalute clinical utility of cpd parameters generated by haematological analyser in diagnosis of both clpd \&viral infection 2-to compare performance of cpd parameters with other established diagnostic \&prognostic markers in clpd


Eligibility criteria:
inclusion criteria: * 1-age \> 18 years old 2- patient newly diagnosed clpd according to the recent who classification; based on bone marrow examination, immunophenotyping \&/or ln biopsy 3- patients are newly diagnosed with viral hepatitis infection based on viral serology exclusion criteria: * 1- patient on treatment 2- patient has both chronic lymphoproliferative disorders and viral hepatitis infection 3- patient has any other' hematological disease 4- patient has any chronic disease affect hematological parameters. 5- patient with incomplete medical records
anecortave acetate for treatment of steroid induced intraocular pressure (iop) elevation

Conditions: Eye Diseases

Summary: the purpose of this study is to evaluate the safety and efficacy of anecortave acetate depot when administered for the treatment of elevated iop following treatment with steroids.


Eligibility criteria:
inclusion criteria: * either gender * 18 years of age or older * iop elevation caused by steroid usage * other protocol-defined inclusion criteria may apply exclusion criteria: * under 18 years of age * other protocol-defined exclusion criteria may apply

Keywords: elevated iop due to intravitreal triamcinolone therapy
intensive care of elderly: what do they wish for themselves?

Conditions: Aged, 80 and Over; Critical Illness

Summary: do very elderly adults wish intensive care in the event of acute life-threatening illness and are their next of kin able to predict these preferences? very elderly patients are a steeply increasing patient population in intensive care units (icus), but the overall benefit of intensive care for these patients remains controversial. will icu admission improve survival and quality of life, or will it prolong suffering and delay natural death? little is known about very elderly norwegians life sustaining treatment (lst) preferences in these situations where treatment benefit is uncertain. this project aims to improve critically ill very elderly patients' icu trajectories by bringing forth knowledge about their treatment preferences, their family members' ability to predict these preferences, and by directing attention to the challenges of consent to critical care in cases of medical uncertainty. a selv administered, mailed survey will be distributed among 400 outpatients aged 80 years or older and their next of kin. respondents will be recruited at the ophthalmologic, ear-nose-and-throat and orthopaedic outpatient clinics at haukeland university hospital bergen, norway. the investigators developed and validated a survey tool for this purpose, containing 3 hypothetical scenarios of acute life-threatening illness. the scenarios are randomly chosen from 20 hypothetical patient histories and are representative for icu admission diagnoses in norway and europe. the participants will be asked for treatment choices, i.e. wishing admission to intensive care or not. a response option 'not wishing to engage in the treatment decision' is also provided. furthermore, the questionnaire includes factors that may influence elderlies' treatment preferences and proxies' ability to predict these preferences including: demographics, religion, previous experience with and / or communication about critical illness, comorbidity, frailty, quality of life, and projections (i.e. the proxy's own treatment preferences). the respondents are requested to explain their choices by free-text comments after each scenario. they are also asked to elaborate how they wish next-of-kin should contribute to decision making in these cases. additional space for free-text comments is provided in the end of the questionnaire. the study design is exploratory. responses will be analysed with both quantitative statistics and qualitative methods.


Eligibility criteria:
inclusion criteria: outpatients aged 80 years or older who register for appointment at the ophthalmologic, ear-nose-and-throat, and orthopaedic outpatient clinic at haukeland university hospital, bergen, norway. exclusion criteria: 1. not consenting to participate 2. living in permanent care facility / nursing home 3. not able to complete the questionnaire owing to: * severely reduced vision / blindness * high degree of frailty (clinical frailty scale ≥ 7) * cognitive impairment

Keywords: consent goals of treatment proxy accuracy shared decision making
ovarian rejuvenation for premature ovarian insufficiency and poor ovarian response

Conditions: Ovarian Failure; Infertility, Female

Summary: the objective of this study is to perform a prospective randomized controlled trial seeking to characterize the effects of intra-ovarian injection of platelet rich plasma (prp) on biomarkers of ovarian reserve as well as ivf outcomes in women with primary ovarian insufficiency (poi) and poor ovarian response (por) who decline the use of an egg donor to establish a pregnancy.

patients will be randomized to either receive the intra-ovarian prp injection procedure or not. regardless of randomization patients will be re-assessed at the same time points for ovarian reserve parameters. if antral follicles are detected at follow up, patients will undergo controlled ovarian hyperstimulation and a routine in vitro fertilization cycle as per protocol.

Eligibility criteria:
inclusion criteria 1. poi according to eshre criteria (patient must fit both criteria): 1. presence of menstrual disturbance defined as oligo/amenorrhea for at least 4 months 2. biochemical confirmation as evidenced by an elevated fsh level \>25 iu/l on two occasions \> 4 weeks apart 2. por defined by at least two prior cycles with por (≤3 oocytes retrieved with a conventional stimulation protocol, or a cancelled cycle due to poor response) 3. patients declining ovum donation treatment exclusion criteria 1. age \ 38yrs 2. autoimmune or sex chromosome etiology of poi 3. ongoing malignancy 4. previous ovarian surgery 5. previous gonadotoxic treatment 6. anticoagulant use for which plasma infusion is contraindicated 7. fmr1 mutations 8. if the duration of the amenorrhea is more than 2 years, patients are discouraged to participate, although it is not an exclusion criterion. 9. patients with only 1 ovary 10. bmi \> 35 11. male partner with \<100,000 total motile spermatozoa per ejaculate (donor sperm is acceptable) 12. surgically obtained sperm 13. presence of hydrosalpinges that communicate with endometrial cavity 14. single gene disorder or chromosomal rearrangement requiring a more detailed embryonic genetic analysis 15. diagnosis of endometrial insufficiency: prior cycle with maximal endometrial thickness ≤ 6mm, abnormal endometrial pattern (failure to attain a trilaminar appearance), persistent endometrial fluid 16. use of a gestational carrier 17. any contraindications to undergoing in vitro fertilization or gonadotropin stimulation 18. known ovaries that are not accessible transvaginally. 19. ovarian endometrioma(s) or dermoid cyst(s) identified via transvaginal ultrasound 20. fsh \> 40iu/l